Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 12.19 is 54% above its 5-year average of 7.90, around the middle of its 5-year range (1.23–17.79).
As of the fiscal period ended Tuesday, June 30, 2026. 110.96% above its 12-month average of 5.78.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.19.
CURRENT RATIO
12.19
CURRENT RATIO AVG TTM
5.78
CURRENT RATIO AVG 3Y
7.32
CURRENT RATIO AVG 5Y
7.90
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+110.96%
CURRENT VS 3Y AVG
+66.56%
CURRENT VS 5Y AVG
+54.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.76
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+224.17%
vs the sector median at left
Market Cap
$359.53M
Current Ratio
5.85
TTM Avg
6.36
3Y Avg
5.52
5Y Avg
8.17
Market Cap
$355.43M
Current Ratio
24.16
TTM Avg
12.00
3Y Avg
8.65
5Y Avg
7.93
Market Cap
$353.88M
Current Ratio
3.76
TTM Avg
4.71
3Y Avg
6.65
5Y Avg
8.92
Market Cap
$369.50M
Current Ratio
5.88
TTM Avg
5.65
3Y Avg
4.80
5Y Avg
5.41
Market Cap
$349.70M
Current Ratio
8.26
TTM Avg
5.36
3Y Avg
5.81
5Y Avg
4.44
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $361.64M | 12.19 | 5.78 | 7.32 | 7.90 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | 5.85 | 6.36 | 5.52 | 8.17 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | 24.16 | 12.00 | 8.65 | 7.93 |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 1.13 | 1.30 | 1.47 | 1.77 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | 3.76 | 4.71 | 6.65 | 8.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | 5.88 | 5.65 | 4.80 | 5.41 |
| Embecta Corp. (EMBC)vs › | $353.00M | 1.68 | 2.22 | 2.19 | 2.04 |
| Ocugen, Inc. (OCGN)vs › | $352.67M | 0.80 | 1.96 | 2.47 | 5.28 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | 8.26 | 5.36 | 5.81 | 4.44 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $374.50M | 9.06 | 8.18 | 5.96 | 5.74 |
Current Ratio
12.19
Quick Ratio
12.19
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 12.19 |
| 2026-03-31 | 7.13 |
| 2025-12-31 | 6.43 |
| 2025-09-30 | 1.23 |
| 2025-06-30 | 1.90 |
| 2025-03-31 | 1.98 |
| 2024-12-31 | 3.24 |
| 2024-09-30 | 6.63 |
| 2024-06-30 | 10.68 |
| 2024-03-31 | 8.96 |
| 2023-12-31 | 13.35 |
| 2023-09-30 | 13.86 |
| 2023-06-30 | 7.54 |
| 2023-03-31 | 10.93 |
| 2022-12-31 | 17.79 |
| 2022-09-30 | 5.41 |
| 2022-06-30 | 5.41 |
| 2022-03-31 | 6.37 |
| 2021-12-31 | 6.76 |
| 2021-09-30 | 8.79 |
| 2021-06-30 | 9.35 |
| 2021-03-31 | 5.24 |
| 2020-12-31 | 5.55 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
